(MENAFN- iCrowdNewsWire)

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the“ mRNA 2.0 Market”- , By Technology (Self-Amplifying mRNA (saRNA), Optimized Non-Amplifying mRNA, Circular RNA (circRNA), Programmable/Logic-Gated mRNA), By Application (Infectious Disease Vaccines, Oncology, Rare & Genetic Diseases, Autoimmune & Inflammatory Diseases, Cardiovascular & Metabolic), By End-User (Hospitals & Clinics, Research Institutions, Biopharmaceutical Companies), and Global Forecasts, 2025-2034 And Segment Revenue and Forecast To 2034.”

mRNA 2.0 market Size is predicted to grow at a 12.8% CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC:

mRNA 2.0 represents the next generation of messenger RNA technologies, developed to address the limitations of first-generation platforms and expand applications beyond infectious disease vaccines. Building on the foundational success of COVID-19 mRNA vaccines, mRNA 2.0 focuses on enhancing molecular stability and optimizing delivery systems.

Given the intrinsic instability of mRNA molecules, these advanced platforms emphasize structurally optimized RNA constructs combined with sophisticated delivery vehicles-such as refined lipid nanoparticles (LNPs), polymer-based carriers, and biologically derived exosomes-to protect against enzymatic degradation and ensure efficient cellular uptake. These innovations also aim to reduce dependence on ultra-cold storage, improving global distribution and accessibility.

A central goal of mRNA 2.0 is targeted delivery and precise protein expression within specific tissues or cell types, which is critical for applications in precision oncology, gene editing, and other therapeutic areas. Accordingly, mRNA 2.0 platforms are increasingly recognized as tools capable of programming RNA for defined biological functions and tissue-specific activity.

Circular RNAs (circRNAs), which are covalently closed single-stranded RNA molecules, are emerging as a key element within the mRNA 2.0 paradigm. Their circular structure provides enhanced molecular stability and supports prolonged protein expression, making them particularly valuable for applications requiring sustained immune activation, such as cancer immunotherapy and vaccines against emerging pathogens.

Unlike linear mRNA, circRNAs demonstrate greater thermostability, remaining viable for extended periods at 4°C or ambient temperatures, thereby reducing cold chain requirements and facilitating deployment in resource-limited settings.

CircRNAs are typically administered using advanced LNP formulations, including mannose-modified variants that enable targeted delivery to lymph nodes and elicit strong immunogenic responses. Lyophilized circRNA-LNP preparations maintain stability post-reconstitution, allowing practical use across diverse clinical environments.

As the mRNA therapeutics market evolves from pandemic-focused applications toward broader treatment areas-including oncology, rare genetic disorders, autoimmune diseases, cardiovascular conditions, and protein replacement therapies-circRNAs, in combination with innovative delivery technologies such as Selective Organ Targeting (SORT) LNPs, polymeric nanoparticles, and exosome-based systems, are driving this transformation.

Their ability to extend expression duration, enhance molecular stability, and reduce dosing frequency positions circRNAs as a critical component of the next wave of RNA-based medical innovation.

List of Prominent Players in the mRNA 2.0 Market:

• Moderna
• BioNTech
• Pfizer
• CureVac
• Arcturus Therapeutics
• GSK
• AstraZeneca
• Merck
• Orna Therapeutics
• Strand Therapeutics
• ReCode Therapeutics
• Abogen Biosciences
• Nutcracker Therapeutics
• Gritstone Bio
• Vertex Pharmaceuticals
• Ethris
• Ziphius Vaccines
• Replicate Bioscience
• Laronde (Senda Biosciences)
• CircBio
• Anima Biotech
• HDT Bio
• VaxEquity
• Voltron Therapeutics
• Chimeron Bio
• MiNA Therapeutics
• Acuitas Therapeutics
• Evox Therapeutics
• DSP
• eTheRNA
• Kernal Biologics

Expert Knowledge, just a Click Away:

Market Dynamics

Drivers:

Advancements in RNA technology-including self-amplifying RNA (saRNA), trans-amplifying RNA (taRNA), optimized non-amplifying mRNA, and circular RNA (circRNA)-are significantly enhancing the therapeutic potential of mRNA-based interventions. These innovations improve molecular stability, increase translational efficiency, reduce dosage requirements, and extend the duration of protein expression, thereby expanding the clinical applicability of mRNA therapeutics across chronic diseases, oncology, and genetic disorders.

Concurrently, the development of sophisticated delivery platforms-such as Selective Organ Targeting (SORT) lipid nanoparticles, polymeric carriers, and exosome-derived vectors-enables precise tissue- and cell-specific localization of mRNA treatments, offering critical advantages for complex therapeutic areas including cancer, neurodegenerative conditions, and metabolic disorders.

Robust financial support from government programs, venture capital investments, and strategic partnerships with pharmaceutical companies is further accelerating research, development, and commercialization of next-generation mRNA therapies.

Challenges:

Despite notable technological advancements, large-scale production of mRNA therapeutics remains constrained by both economic and technical factors. Manufacturing processes require specialized, high-cost reagents, including custom enzymes and chemically modified nucleotides, which increase overall production expenses.

In addition, rigorous purification protocols are necessary to remove impurities, such as double-stranded RNA, which can elicit undesired immune responses. These complexities present significant scalability challenges and may limit broader adoption, particularly in regions lacking advanced biomanufacturing infrastructure.

Regional Trends:

North America, led by the United States, maintains a dominant position in the mRNA 2.0 market, supported by a robust scientific ecosystem, advanced regulatory frameworks, extensive R&D infrastructure, and sustained investment from both public and private sectors. These factors position the region as a global hub for innovation and commercialization of RNA-based therapeutics.

The Asia-Pacific region is expected to experience the fastest growth, driven by strategic national initiatives to develop indigenous mRNA research and manufacturing capabilities. Key markets, including China, India, Japan, and South Korea, are investing substantially in infrastructure, talent cultivation, and clinical research programs to strengthen their global competitiveness.

The rapid expansion of early- and mid-stage clinical trials, alongside scaling of regional Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs), highlights the region's commitment to meeting growing demand from both domestic and international biopharmaceutical companies.

Unlock Your GTM Strategy:

Recent Developments:

• In Apr 2025, Arcturus Therapeutics Holdings Inc. declared that the U.S. Food and Drug Administration (FDA) has awarded Fast Track Designation to ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate intended for active immunization to prevent disease caused by influenza A H5N1 subtype contained in the vaccine. The study was centered on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases.
• In Aug 2024, Abogen Biosciences, revealed a paper in Nucleic Acids Research titled“Efficient circularization of protein-encoding RNAs via a novel cis-splicing system.” The production of circular RNA (“circRNA”) with greatly increased protein expression, decreased innate immune activation, and flexible splice site design that offers significant market potential is made possible by Abogen's highly effective RNA circularization cis-splicing system (referred to as the“Cis-System”), which was disclosed in the article. The biopharmaceutical sector has shown a great deal of interest in circular RNA technology, and a number of circular RNA start-ups have garnered more than $1 billion in funding.

Segmentation of mRNA 2.0 Market.

Global mRNA 2.0 Market – By Technology

• Self-Amplifying mRNA (saRNA)
• Optimized Non-Amplifying mRNA
• Circular RNA (circRNA)
• Programmable/Logic-Gated mRNA

Global mRNA 2.0 Market – Infectious Disease Vaccines

• Oncology
• Rare & Genetic Diseases
• Autoimmune & Inflammatory Diseases
• Cardiovascular & Metabolic

Global mRNA 2.0 Market – By End-User

• Hospitals & Clinics
• Research Institutions
• Biopharmaceutical Companies

Global mRNA 2.0 Market – By Region

North America-

• The US
• Canada

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa-

• GCC Countries
• South Africa
• Rest of the Middle East and Africa

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Disclaimer: The iCrowdNewswire provides distribution services for Research Marketing reports, however, it does not assume any responsibility for the content (facts, opinions, photos, or any other part of it) of the reports. All responsibility of the content is with the publisher of the report.

Tags: mRNA 2.0 Market See Campaign:
Contact Information:

Contact us: InsightAce Analytic Pvt. Ltd. Visit: Tel: +1 607 400-7072 Asia: +91 79 72967118...

Tags:
CE, Go Media, Go Media2, iCN Internal Distribution, Reportedtimes, Research Newswire, English

MENAFN17102025003318003403ID1110212913